A recent CAR-T trial has shown encouraging results, indicating that it may help prevent smoldering multiple myeloma from advancing into active disease.
This development is particularly significant for patients identified as high-risk, who may benefit from early intervention.
While these results are promising, further research will be necessary to fully understand the implications and effectiveness of this treatment approach.